Tardive Dyskinesia

Epidemiology, Pathophysiology, and Pharmacology
  • Jes Gerlach
  • Daniel E. Casey
  • Søren Korsgaard


Two decades ago, Faurbye and co-workers at Saint Hans Hospital introduced the term tardive dyskinesia (TD) to designate the now well-known syndrome of involuntary hyperkinetic movements that may develop during or following long-term treatment with neuroleptic drugs (Uhrbrand and Faurbye, 1960; Faurbye et al.,1964). In recent years, TD has attracted increasing attention, not only from psychiatrists faced with this serious side effect of an otherwise beneficial antipsychotic treatment, but also from pharmacologists and neurochemists who recognized TD as a valid clinical correlate to the behavioral and biochemical effects of neuroleptic drugs in animals. The syndrome has therefore been the subject of a large number of clinical and animal investigations (for book reviews, see Baldessarini et al.,1980; Fann et al.,1980; DeVeaugh-Geiss, 1982; Jeste and Wyatt, 1982; Bannet and Belmaker, 1983; Klawans, 1983; Casey and Gerlach, 1984; Casey et al., 1985).


Tardive Dyskinesia Neuroleptic Drug Neuroleptic Treatment Gaba Neuron Gaba Agonist 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Asnis, G. M., and Leopold, M. A., 1978, A single-blind study of ECT in patients with tardive dyskinesia, Am. J. Psychiatry. 135: 1235.PubMedGoogle Scholar
  2. Baldessarini, R. J., Cole, J. O., Davis, J. M., Gardos, G., Preskorn, S. H., Simpson, G. M., and Tarsy, D., 1980, Tardive dyskinesia: A task force report, American Psychiatric Association, American Psychiatric Press, Washington D.C.Google Scholar
  3. Bannet, J., and Belmaker, R. H., 1983, New Directions in Tardive Dyskinesia Research, Karger, Basel.Google Scholar
  4. Beitman, B. D., 1978, Tardive dyskinesia reinduced by lithium carbonate, Am. J. Psychiatry 135: 1229.PubMedGoogle Scholar
  5. Bell, R. C. H., and Smith, R. C., 1978, Tardive dyskinesia: Characterization and prevalence in a statewide system, J. Clin. Psychiatry 39: 39.PubMedGoogle Scholar
  6. Brandrup, E., 1961, Tetrabenazine treatment in persisting dyskinesia caused by psychopharmaca, Am. J. Pyschiatry 118: 551.Google Scholar
  7. Carlsson, A., 1975, Receptor-mediated control of dopamine metabolism, in: Pre-and Postsynpatic Receptors ( E. Usdin and W. E. Bunney, eds.), pp. 49–63, Marcel Dekker Inc., New York.Google Scholar
  8. Carroll, B. J., Curtis, C. C., and Kokmen, E., 1977, Paradoxical response to dopamine agonists in tardive dyskinesia, Am. J. Psychiatry 134: 785.PubMedGoogle Scholar
  9. Casey, D. E., 1977, Deanol in the management of involuntary movement disorders: A review, Dis. Nerv. Syst. 38: 7.PubMedGoogle Scholar
  10. Casey, D. E., 1984, Tardive dyskinesia and affective disorders, in: Tardive Dyskinesia and Affective Disorders ( G. Gardos and D. E. Casey, eds.), pp. 2–17, American Psychiatric Press, Washington, DC.Google Scholar
  11. Casey, D. E., 1985a, Spontaneous and tardive dyskinesia: Clinical and laboratory studies, J. Clin. Psychiatry 46: 42–47.PubMedGoogle Scholar
  12. Casey, D. E., 1985b, Behavioral effects of long-term neuroleptic treatment in Cebus monkeys, in: Dyskinesia—Research and Treatment (Psychopharmacoloy, Suppl. 2) ( D. E. Casey, T. Chase, A. V. Christensen, and J. Gerlach, eds.), pp. 211–216, Springer-Verlag, Berlin, Heidelberg.Google Scholar
  13. Casey, D. E., and Denney, D., 1977, Pharmacological characterization of tardive dyskinesia, Psychopharmacology 54: 1.PubMedCrossRefGoogle Scholar
  14. Casey, D. E., and Gerlach, J., 1984, Tardive dyskinesia: management and new treatment, in: Guidelines for the Use of Psychotropic Drugs ( H. C. Stancer, P. E. Garfinkel, and V. M. Rakoff, eds.), pp. 183–203, Spectrum, New York.Google Scholar
  15. Casey, D. E., and Hansen, T. E., 1984, Spontaneous dyskinesia, in: Neuropsychiatric Movement Disorders (D. V. Jeste and R. J. Wyatt, eds.), pp. 68–95, American Psychiatric Press, Washington, DC.Google Scholar
  16. Casey, D. E., and Rabins, P., 1978, Tardive dyskinesia as a life-threatening illness, Am. J. Psychiatry 135: 486.PubMedGoogle Scholar
  17. Casey, D. E., and Toenniessen, L. M., 1983, Neuroleptic treatment in tardive dyskinesia; can it be developed into a clinical strategy for long-term treatment? in: New Directions in Tardive Dyskinesia Research ( J. Bannet and R. H. Belmaker, eds.), pp. 65–79, Karger, Basel.Google Scholar
  18. Casey, D. E., Gerlach, J., and Christensson, E., 1980, Dopamine, acetylcholine, and GABA effects in acute dystonia in primates, Psychopharmacology 70: 83.PubMedCrossRefGoogle Scholar
  19. Casey, D. E., Gerlach, J., Magelund, G., and Rosted Christensen, T., 1980b, -y-Acetylenic GABA in tardive dyskinesia, Arch. Gen. Psychiatry 37: 1376.Google Scholar
  20. Casey, D. E., Korsgaard, S., Gerlach, J., Jorgensen, A., and Simmelsgaard, H., 1981, Effect of des-tyrosine-ry-endorphin in tardive dyskinesia, Arch. Gen. Psychiatry 38: 158.PubMedCrossRefGoogle Scholar
  21. Casey, D. E., Gerlach, J., and Bj¢rndal, N., 1982, Levodopa and receptor sensitivity modification in tardive dyskinesia, Psychopharmacology 78: 89.PubMedCrossRefGoogle Scholar
  22. Casey, D. E., Chase, T., Christensen, A. V., and Gerlach, J., 1985, Dyskinesia—Research and Treatment (Psychopharmacology, Suppl. 2 ), Springer-Verlag, Berlin, Heidelberg.Google Scholar
  23. Chase, T. M., and Tamminga, C. A., 1979, GABA system participation in motor, cognitive and endocrine function in man, in: GABA-Neurotransmitters. Pharmacochemical, Biochemical and Pharmacological Aspects ( P. Krogsgaard-Larsen, J. Scheel-Krüger, and.H. Kofod, eds.), pp. 283–296, Academic Press, New York.Google Scholar
  24. Chase, T. N., and Tamminga, C. A., 1980, Pharmacological studies of tardive dyskinesia, in: Long Term effects of neuroleptics, Advances in Biochemical Psychopharmacology Vol. 24 ( F. Cattabeni, G. Racagni, P. F. Spano, and E. Costa, eds.), pp. 457–461, Raven Press, New York.Google Scholar
  25. Chase, T. N., Watanabe, A. M., Brodie, K. H., and Donnelly, E. F., 1972, Huntington’s chorea. Effect of serotonin depletion, Arch. Neurol. 26: 282.PubMedCrossRefGoogle Scholar
  26. Christensen, A. V., 1981, Dopamine hyperactivity: Effects of neuroleptics alone and in combination with GABA agonists, in: Biological Psychiatry 1981 ( C. Perris, G. Struwe, and B. Jansson, eds.), pp. 828–832, Elsevier/North Holland, Amsterdam.Google Scholar
  27. Christensen, A. V., Arnt, J., and Svendsen, O., 1985, Pharmacological differentiation of dopamine D-1 and D-2 antagonists after single and repeated administration, in: Dyskinesia—Research and Treatment (Psychopharmacology, Suppl. 2) ( p. E. Casey, T. Chase, A. V. Christensen, and J. Gerlach, eds.), pp. 182–190, Springer-Verlag, Berlin, Heidelberg.Google Scholar
  28. Claghorn, J. L., Abuzzahab, F. S., Wang, R., Larson, C., Gelenberg, A. J., Klerman, G. L., Tuason, V., and Steinbook, R., 1983, The current status of clozapine, Psychopharmacol. Bull. 19: 138.Google Scholar
  29. Claveria, L. E., Teychenne, P. F., Caine, D. B., Haskayne, L., Petrie, A., Pallis, C. A., and Lodge-Patch, I. C., 1975, Tardive dyskinesia treated with pimozide, J. Neurol. Sci. 24: 393.PubMedCrossRefGoogle Scholar
  30. Cools, A. R., and Van Rossum, J. M., 1976, Excitation-mediating and inhibition-mediating dopamine-receptors: A new concept towards a better understanding of electrophysiological, biochemical, pharmacological, functional and clinical data, Psychopharmacologia 45: 243.PubMedCrossRefGoogle Scholar
  31. Coward, D. M., 1982, Classical and non-classical neuroleptics induce supersensitivity of nigral GABA-ergic mechanisms in the rat, Psychopharmacology 78: 180.PubMedCrossRefGoogle Scholar
  32. Crane, G. E., 1973, Persistent dyskinesia, Br. J. Psychiatry 122: 395.PubMedCrossRefGoogle Scholar
  33. Crow, T. J., Cross, A. J., Johnstone, E. C., Owen, F., Owens, D. G. C., and Waddington, J. L., 1982, Abnormal involuntary movements in schizophrenia: Are they related to the disease process or its treatment? Are they associated with changes in dopamine receptors? J. Clin. Psychopharmacol. 2: 336.PubMedCrossRefGoogle Scholar
  34. DeVeaugh-Geiss, J., 1982, Tardive Dyskinesia and Related Involuntary Movement Disorders, John Wright, PSG Inc., Boston-Bristol-London.Google Scholar
  35. De Wied, D., Kovacs, G. L., Bohus, B., Van Ree, J. M., and Greven, H. M., 1978, Neuroleptic activity of the neuropeptide 3-LPH62_77(des-tyr-1-y-endorphin (DTyE), Eur. J. Pharmacol. 49: 427.PubMedCrossRefGoogle Scholar
  36. Doepp, S., and Buddeberg, C., 1975, Extrapyramidale Symptome unter Clozapin, Nervenarzt 46: 589.PubMedGoogle Scholar
  37. Domino, E. F., 1985, Induction of tardive dyskinesia in Cebus apella and Macaca speciosa monkeys: A review, in: Dyskinesia—Research and Treatment (Psychopharmacology, Suppl. 2) ( D. E. Casey, T. Chase, A. V. Christensen, and J. Gerlach, eds.), pp. 217–223, Springer-Verlag, Berlin, Heidelberg.Google Scholar
  38. Edwards, H., 1970, The significance of brain damage in persistent oral dyskinesia, Br. J. Psychiatry 116: 271.PubMedCrossRefGoogle Scholar
  39. Eichenberger, E., 1984, Pharmacology of fluperlapine compared with clozapine. Arzneim.-Forsch.l Drug Res. 34: 110.Google Scholar
  40. Ettigi, P., Nair, N. P. V., Lal, S., Cervantes, P., and Guyda, H., 1976, Effect of apomorphine on growth hormone and prolactin secretion in schizophrenic patients, with or without oral dyskinesia, withdrawn from chronic neuroleptic therapy, J. Neurol. Neurosurg. Psychiatry 39: 870.PubMedCrossRefGoogle Scholar
  41. Fann, W. E., Smith, R. C., Davis, J. M., and Domino, E. F., 1980, Tardive Dyskinesia. Research and Treatment, Spectrum, Jamaica, New York.Google Scholar
  42. Faurbye, A., Rasch, P. J., Petersen, P. B., Brandborg, G., and Pakkenberg, H., 1964, Neurological symptoms in pharmacotherapy in psychoses, Acta Psychiatr. Scand. 40: 10.PubMedCrossRefGoogle Scholar
  43. Fibiger, H. C., and Lloyd, K. G., 1984, Neurobiological substrates of tardive dyskinesia: The GABA hypothesis, Trends In Neuroscience, p. 462.Google Scholar
  44. Fischer-Cornelssen, K. A., 1984, Fluperlapine in 104 schizophrenic patients. Open multicenter trial, Arzneim.-Forsch./Drug. Res. 34: 125.Google Scholar
  45. Fog, R., Pakkenberg, H., Juul, P., Bock, E., J¢rgensen, O. S., and Andersen, J., 1976, High-dose treatment of rats with perphenazine enanthate, Psychopharmacology 50: 305.Google Scholar
  46. Friedhoff, A. J., Bonnet, K., and Rosengarten, H., 1977, Reversal of two manifestations of dopamine receptor supersensitivity by administration of L-dopa, Res. Commun. Chem. Pathol. Pharmacol. 16: 411.PubMedGoogle Scholar
  47. Gale, K., and Casu, M., 1981, Dynamic utilization of GABA in substantia nigra: Regulation by dopamine and GABA in the striatum, and its clinical and behavioral implications, Mol. Cell Biochem. 39: 369.PubMedCrossRefGoogle Scholar
  48. Gardos, G., and Cole, J. O., 1978, Pilot study of cyproheptadine (Periactin) in tardive dyskinesia, Psychopharmacol. Bull. 14: 18.PubMedGoogle Scholar
  49. Gardos, G., Cole, J., and La Brie, R., 1977, Drug variables in the etiology of tardive dyskinesia. Application of discriminant function analyses, Prog. Neurol. Psychopharmacol. 1: 147.CrossRefGoogle Scholar
  50. Gardos, G., Perenyi, A., and Cole, J. O., 1983, Tardive dyskinesia: Changes after three years, J. Clin. Psychopharmacol. 3: 315.PubMedGoogle Scholar
  51. Gerlach, J., 1979, Tardive dyskinesia, Dan. Med Bull. 46: 209.Google Scholar
  52. Gerlach, J., and Casey, D. E., 1983, Dopamine agonists in clinical research for new tardive dyskinesia treatment, in: New Directions in Tardive Dyskinesia Research ( J. Bannet and R. H. Belmaker, eds.), pp. 97–110, Karger, Basel.Google Scholar
  53. Gerlach, J., and Casey, D. E., 1984, Sulpiride in tardive dyskinesia, Acta Psychiatr. Scand. 69 (Suppl. 311): 93.CrossRefGoogle Scholar
  54. Gerlach, J., and Korsgaard, S., 1981, Classification and prevalence of neuroleptic-induced hyperkinetic disorders, in: Biological Psychiatry 1981 ( C. Perris, G. Struwe, and B. Jansson, eds.), pp. 844–851, Elsevier/North Holland, Amsterdam.Google Scholar
  55. Gerlach, J., and Simmelsgaard, H., 1978, Tardive dyskinesia during and following treatment with haloperidol, haloperidol + biperiden, thioridazine and clozapine, Psychopharmacology 59: 105.PubMedCrossRefGoogle Scholar
  56. Gerlach, J., and Thorsen, K., 1976, The movement pattern of oral tardive dyskinesia in relation to anticholinergic and antidopaminergic treatment, Int. J. Pharmacopsychiatr. 11: 1.Google Scholar
  57. Gerlach, J., Koppelhus, P., Jelweg, E., and Monrad, A., 1974a, Clozapine and haloperidol in a single-blind cross-over trial: Therapeutic and biochemical aspects in the treatment of schizophrenia, Acta Psychiatr. Scand. 50: 410.PubMedCrossRefGoogle Scholar
  58. Gerlach, J., Reisby, N., and Randrup, A., 1974b, Dopaminergic hypersensitivity and cholinergic hypofunction in the pathophysiology of tardive dyskinesia, Psychopharmacologia 34: 21.PubMedCrossRefGoogle Scholar
  59. Gerlach, J., Thorsen, K., and Fog, R., 1975, Extrapyramidal reactions and amine metabolites in cerebrospinal fluid during haloperidol and clozapine treatment of schizophrenic patients, Psychopharmacologia 40: 341.PubMedCrossRefGoogle Scholar
  60. Glazer, W. M., Moore, D. C., Schooler, N. R., Brenner, L. M., and Morgenstern, H., 1984, Tardive dyskinesia. A discontinuation study, Arch. Gen. Psychiatry 41: 623.CrossRefGoogle Scholar
  61. Gottfries, C. G., 1981, Levels of monoamines, monoamine metabolites, and activity in related enzyme systems correlated to normal aging and in patients with dementia of Alzheimer type, in: Apomorphine and Other Dopaminomimetics, vol. 2, Clinical Pharmacology ( G. U. Corsini and G. L. Gessa, eds.), pp. 243–249, Raven Press, New York.Google Scholar
  62. Gunne, L-M., and B’aräny, S., 1979, A monitoring test for the liability of neuroleptic drugs to induce tardive dyskinesia, Psychopharmacology 63: 195.PubMedCrossRefGoogle Scholar
  63. Gunne, L. M., and Bârany, S., 1980, A primate model for tardive dyskinesia, in: Tardive Dyskinesia: Research and Treatment ( W. E. Fann, R. C. Smith, and J. M. Davis, eds.), pp. 1–26, Spectrum, New York.CrossRefGoogle Scholar
  64. Gunne, L.-M., Häggström, J.-E., and Sjöquist, B., 1984, Persistent neuroleptic-induced dyskinesia associated with regional changes within brain GABA and dopamine systems, Nature (London) 309: 347.CrossRefGoogle Scholar
  65. Hardie, R. J., Lees, A. J., and Stern, G. M., 1983, Sustained levodopa therapy in tardive dyskinesia, J. Neurol. Neurosurg. Psychiatry 46: 685.PubMedCrossRefGoogle Scholar
  66. Hjorth, S., Carlsson, A., Wikström, H., Lindberg, P., Sanchez, D., Hackseil, U., Arvidsson, L. E., Svensson, U., and Nilsson, J. L. G., 1981, 3-PPP, a new acting DA-receptor agonist with selectivity for autoreceptors, Life Sci. 28: 1225.Google Scholar
  67. Itoh, H., and Yagi, G., 1979, Reversibility of tardive dyskinesia, Folia Psychiat. Neurolog. Jap. 33: 43.Google Scholar
  68. Iversen, L. L., 1979, The chemistry of the brain, Sci. Am. 241: 134.PubMedCrossRefGoogle Scholar
  69. Jenner, P., and Marsden, C. D., 1981, Substituted benzamide drugs as selective neuroleptic agents, Neuropharmacology 20: 1285.PubMedGoogle Scholar
  70. Jeste, D. V., and Wyatt, R. J., 1982, Understanding and Treating Tardive Dyskinesia, The Guilford Press, New York.Google Scholar
  71. Jus, K., Jus, A., Gautier, J., Villeneuve, A., Pires, P., Pineau, R., and Villeneuve, R., 1974, Studies on the action of certain pharmacological agents on tardive dyskinesia and on the rabbit syndrome, Int. J. Clin. Pharmacol. 9: 138.PubMedGoogle Scholar
  72. Kane, J. M., and Smith, J. M., 1982, Tardive dyskinesia: Prevalence and risk factors, 1959 to 1979, Arch. Gen. Psychiatry 39: 473.PubMedCrossRefGoogle Scholar
  73. Kane, J. M., Woerner, M., and Lieberman, J., 1985, Tardive dyskinesia: Prevalence, incidence, and risk factors, in: Dyskinesia—Research and Treatment (Psychopharmacology, Suppl. 2) ( D. E. Casey, T. Chase, A. V. Christensen, and J. Gerlach, eds.), pp. 72–78, Springer-Verlag, Berlin, Heidelberg.Google Scholar
  74. Kazamatsuri, H., Chien, C. P., and Cole, J., 1972, Treatment of tardive dyskinesia. II. Short-term efficacy of dopamine-blocking agents haloperidol and thiopropazate, Arch. Gen. Psychiatry 27: 100.PubMedCrossRefGoogle Scholar
  75. Klawans, H. L. (ed.), 1983, Proceedings of a symposium on tardive dyskinesia. Clin. Neuropharmacol. 6:75.Google Scholar
  76. Klawans, H. L., and Rubovits, R., 1974, Effect of cholinergic and anticholinergic agents on tardive dyskinesia, J. Neurol. Neurosurg. Psychiatry 27: 941.CrossRefGoogle Scholar
  77. Klawans, H. L., Goetz, C. G., and Perlik, S., 1980, Tardive dyskinesia: Review and update, Am. J. Psychiatry 137: 900.PubMedGoogle Scholar
  78. Korsgaard, S., Casey, D. E., Gerlach, J., Hetmar, O., Kaldan, B., and Mikkelsen, L. B., 1982a, Effect of THIP, a new GABA agonist in tardive dyskinesia, Arch. Gen. Psychiatry 39: 1017.PubMedCrossRefGoogle Scholar
  79. Korsgaard, S., Casey, D. E., and Gerlach, J., 1982b, High-dose des-tyrosine-y-endorphin in tardive dyskinesia, Psychopharmacology 78: 285.PubMedCrossRefGoogle Scholar
  80. Korsgaard, S., Gerlach, J., and Christensson, E., 1982c, Behavioural aspects of serotonin-dopamine interactions in monkeys, in: CINP Congress Abstracts, Jerusalem, p. 400.Google Scholar
  81. Korsgaard, S., Casey, D. E., and Gerlach, J., 1983, Effect of ti-vinyl GABA in tardive dyskinesia, Psychiatr. Res. 8: 261.CrossRefGoogle Scholar
  82. Korsgaard, S., Noring, U., and Gerlach, J., 1984, Fluperlapine in tardive dyskinesia and parkinsonism, Psychopharmacology 84: 76.PubMedCrossRefGoogle Scholar
  83. Lee, D. K., Markham, C. H., and Clark, W. G., 1969, Serotonin (5-HT) in Huntington’s chorea, in: Progress in Neurogenetics ( A. Barbeau and J. R. Brunette, eds.), Excerpta Medica Foundation, Amsterdam.Google Scholar
  84. Lühdorf, K., and Lund, M., 1977, Phenytoin induced hyperkinesia, Epilepsia 18: 409.PubMedCrossRefGoogle Scholar
  85. Magelund, G., Gerlach, J., and Casey, D. E., 1979, Neuroleptic-potentiating effect of a-methylp-tyrosine compared with haloperidol and placebo in a double-blind cross-over trial, Acta Psychiatr. Scand. 60: 185.PubMedCrossRefGoogle Scholar
  86. Marsden, C. D., 1985, Is tardive dyskinesia a unique disorder? in: Dyskinesia—Research and Treatment (Psychopharmacology, Suppl. 2) ( D. E. Casey, T. Chase, A. V. Christensen, and J. Gerlach, eds.), pp. 64–71, Springer-Verlag, Berlin, Heidelberg.Google Scholar
  87. Marsden, C. D., and Jenner, P., 1981, The nature and selectivity of changes in cerebral neuronal receptor function induced by continuous long term neuroleptic administration to rats, in: Biological Psychiatry 1981 ( C. Perris, G. Struwe, and B. Jansson, eds.), pp. 820–823, Elsevier/ North Holland, Amsterdam.Google Scholar
  88. Meldrum, B., 1982, Pharmacology of GABA, Clin. Neuropharmacol. 5: 293.PubMedCrossRefGoogle Scholar
  89. Meltzer, H. Y., 1982, Dopamine autoreceptor stimulation: Clinical significance, Pharmacol. Biochem. Behavior 17 (suppl. 1): 1.CrossRefGoogle Scholar
  90. Morselli, P. L., Fournier, V., Bossi, L., and Musch, B., 1985, Clinical activity of GABA agonists in neuroleptic-and L-dopa-induced dyskinesia, in: Dyskinesia—Research and Treatment (Psychopharmacology, Suppl. 2) ( D. E. Casey, T. Chase, A. V. Christensen, and J. Gerlach, eds.), pp. 128–136, Springer-Verlag, Berlin, Heidelberg.Google Scholar
  91. Nasrallah, H. A., Donnelly, E. F., Bigelow, L. B., Rivera-Calimlim, L., Rogol, A., Potkin, S., Rauscher, F. P., Wyatt, R. J., and Gillin, J. C., 1977, Inhibition of dopamine synthesis in chronic schizophrenia, Arch Gen. Psychiatry 34: 649.PubMedCrossRefGoogle Scholar
  92. Nasrallah, H. A., Smith, R. E., Dunner, F. J., and McCalley-Whitters, M., 1982, Serotonin precursor effects in tardive dyskinesia, Psychopharmacology 77: 234.PubMedCrossRefGoogle Scholar
  93. Nasrallah, H. A., Dunner, F. J., Smith, R. E., McCalley-Whitters, M., 1983, A placebo-controlled trial of L-dopa in tardive dyskinesia, Psychopharmacol. Bull. 19: 122.Google Scholar
  94. Nielsen, E. B., and Lyon, M., 1978, Evidence for cell loss in corpus striatum after longterm treatment with a neuroleptic drug (fluopenthixol) in rats, Psychopharmacology 59: 85.PubMedCrossRefGoogle Scholar
  95. Noring, U., Juul Povlsen, U., Casey, D. E., and Gerlach, J., 1984, Effect of a cholinomimetic drug (RS 86) in tardive dyskinesia and drug-related parkinsonism, Psychopharmacology 84: 569.PubMedCrossRefGoogle Scholar
  96. Owens, D. G. C., 1985, Involuntary disorders of movement in chronic schizophrenia—The role of the illness and its treatment, in: Dyskinesia—Research and Treatment (Psychopharmacology, Suppl. 2) ( D. E. Casey, T. Chase, A. V. Christensen, and J. Gerlach, eds.), pp. 7987, Springer-Verlag, Berlin, Heidelberg.Google Scholar
  97. Pakkenberg, H., Fog, R., and Nilakantan, B., 1973, The long-term effects of perphenazine enanthate on the rat brain, Psychopharmacologia 29: 329.PubMedCrossRefGoogle Scholar
  98. Pi, E. H., and Simpson, G. M., 1983, Atypical neuroleptics Clozapine and the benzamides in the prevention and treatment of tardive dyskinesia, in: New Directions in Tardive Dyskinesia Research ( J. Bannet and R. H. Belmaker, eds.), pp. 80–86, Karger, Basel.Google Scholar
  99. Price, T. R. P., and Levin, R., 1978, The effects of electroconvulsive therapy on tardive dyskinesia, Am. J. Psychiatry 135: 991.PubMedGoogle Scholar
  100. Rosenbaum, A. H., Niven, R. G., Hanson, N. P., et al.,1977, Tardive dyskinesia: Relationship with a primary affective disorder, Dis. Nerv. Syst. 38:423.Google Scholar
  101. Scheel-Krüger J., 1983, The GABA receptor and animal behaviour evidence that GABA transmits and mediates dopaminergic functions in the basal ganglia and the limbic system, in: GABA Receptors ( S. J. Enna, ed.), pp. 215–255, Humana Press, Clifton, NJ.Google Scholar
  102. Scheel-Krüger, J., and Arnt, J., 1985, New aspects on the role of dopamine, acetylcholine, and GABA in the development of tardive dyskinesia, in: Dyskinesia—Research and Treatment (D. E. Casey, T. Chase, A. V. Christensen, and J. Gerlach, eds.) (Psychopharmacology, Suppl. 2), pp. 46–71, Springer-Verlag, Berlin, Heidelberg.Google Scholar
  103. Schönecker, M., 1957, Ein eigentümliches Syndrom im oralen Bereich bei Megaphenapplikation, Nervenarzt 28: 35.Google Scholar
  104. Seeman, P., 1980, Brain dopamine receptors, Pharmacol. Rev. 32: 229.PubMedGoogle Scholar
  105. Shah, N. S., and Donald, A. G., 1982, Endorphins and Opiate Antagonists in Psychiatric Research, Plenum Medical, New York, London.CrossRefGoogle Scholar
  106. Sigwald, J., Bouttier, D., Raymondeaud, C., et al.,1959, Quatre cas de dyskinésie facio-buccolinguo-masticatrice a l’evolution prolongée secondaire à un traitement par les neuroleptiques, Rev. Neurol. 100:751.Google Scholar
  107. Simpson, G., Lee, J., and Shrivastava, R., 1978, Clozapine in tardive dyskinesia, Psychopharmacology 56: 75.PubMedCrossRefGoogle Scholar
  108. Smith, J. M., and Baldessarini, R. J., 1980, Changes in prevalence, severity and recovery in tardive dyskinesia with old age, Arch. Gen. Psychiatry 37: 1368.PubMedCrossRefGoogle Scholar
  109. Smith, R. C. Tamminga, C. A., Haraszti, J., Pandey, G. N., and Davis, J. M., 1977, Effects of dopamine agonists in tardive dyskinesia, Am. J. Psychiatry 134: 763.PubMedGoogle Scholar
  110. Tamminga, C. A., Smith, R. C., Pandey, G., Frohman, L. A., and Davis, J. M., 1977, A neuroendocrine study of supersensitivity in tardive dyskinesia, Arch. Gen. Psychiatry 34: 1199.PubMedCrossRefGoogle Scholar
  111. Tamminga, C. A., Crayton, J. W., and Chase, T. N., 1979, Improvement in tardive dyskinesia after muscimol therapy, Arch. Gen. Psychiatry 36: 595.PubMedCrossRefGoogle Scholar
  112. Tamminga, C. A., Thaker, G. K., and Chase, T. N., 1985, GABA dysfunction in the pathophysiology of tardive dyskinesia, in: Dyskinesia—Research and Treatment (Psychopharmacology, Suppl. 2) ( D. E. Casey, T. Chase, A. V. Christensen, and J. Gerlach, eds.), pp. 122–127, Springer-Verlag, Berlin, Heidelberg.Google Scholar
  113. Tarsy, D., Leopold, N., and Sax, D., 1974, Physostigmine in choreiform movement disorders, Neurology 24: 28.PubMedGoogle Scholar
  114. Thach, B. T., Chase, T. N., and Bosma, J. F., 1975, Oral facial dyskinesia associated with prolonged use of antihistaminic decongestants, N. Engl. J. Med. 293: 486.PubMedCrossRefGoogle Scholar
  115. Toenniessen, L. M., and Casey, D. E., 1982, Duration of neuroleptic exposure and risk of tardive dyskinesia, Proc. Soc. Biol. Psychiatry 69: 100.Google Scholar
  116. Toenniessen, L. M., Casey, D. E., and McFarland, B. H., 1985, Tardive dyskinesia in the aged: Duration of treatment relationships, Arch. Gen. Psychiatry 42: 278–284.PubMedCrossRefGoogle Scholar
  117. Uhrbrand, L., and Faurbye, A., 1960, Reversible and irreversible dyskinesia after treatment with perphenazine, chlorpromazine, reserpine and electroconvulsive therapy, Psychopharmacologia 1: 408.CrossRefGoogle Scholar
  118. Wàlinder, J., Skott, A., Carlsson, A., and Ross, B. E., 1976, Potentiation by metyrosine of thioridazine effects in chronic schizophrenics, Arch. Gen. Psychiatry 33: 501.PubMedCrossRefGoogle Scholar
  119. Weiss, B., and Santelli, S., 1978, Dyskinesias evoked in monkeys by weekly administration of haloperidol, Science 200: 799.PubMedCrossRefGoogle Scholar
  120. Woggon, B., Heinrich, K., Küfferle, B., Müller-Oerlinghausen, B., Pöldinger, W., Rüther, E., and Schied, H. W., 1984, Results of a multicenter AMDP study with fluperlapine in schizophrenic patients, Arzneim.-Forsch./Drug Res. 34: 122.Google Scholar

Copyright information

© Plenum Publishing Corporation 1986

Authors and Affiliations

  • Jes Gerlach
    • 1
  • Daniel E. Casey
    • 2
  • Søren Korsgaard
    • 1
  1. 1.Department HSaint Hans HospitalRoskildeDenmark
  2. 2.Departments of Psychiatry, Research, and NeurologyVeterans Administration Medical Center and Oregon Health Sciences UniversityPortlandUSA

Personalised recommendations